A Field Split Between the Scalpel and the Symptom Score.
Regulatory strategy across urology — where devices clear on flow rates and drugs approve on what a patient records in a diary.
Urology Is Where CDER and CDRH Review the Same Patient.
A man with an enlarged prostate can be treated with a daily tablet reviewed by CDER on a symptom score, or with a steam ablation device reviewed by CDRH on flow rate and adverse events. Same indication, same patient, entirely different evidence, timelines, and reviewers. Urology sponsors routinely misjudge which building they are walking into.
The field's device side is unusually crowded with minimally invasive procedures competing directly against pharmacotherapy — which makes the comparator choice and the claim language commercially decisive. We map the pathway to the claim first, then build the program the right reviewer will accept.
BPH can be a drug on a symptom score or a device on a flow rate. The choice sets everything downstream.
The Same Indication, Routed Two Ways.
Urology's defining regulatory question is which center owns your product — and the answer changes the endpoint, the trial, the timeline, and the label.
IPSS symptom score over 12 weeks, placebo-controlled, with sexual-function safety scrutinised closely.
Qmax flow rate and IPSS with a sham or active control, retreatment rate followed for years.
Micturition and incontinence episodes from a validated bladder diary — the patient is the instrument.
Slings and bulking agents in a post-mesh world: PMA scrutiny, long follow-up, and a chastened reviewer.
MFS and OS endpoints in the Oncology Center of Excellence — a different division and a different culture.
Lasers and lithotripsy on stone-free rates, largely 510(k), where the predicate space is deep.
The mesh era is the field's inheritance. Transvaginal mesh moved to Class III, took PMA requirements, and left urology's device reviewers permanently more demanding about long-term safety follow-up. Any implant that touches the lower urinary tract inherits that skepticism whether or not it deserves it.
Six Corners of Urology, Six Evidence Bars.
Each corner has its own accepted endpoint, its own comparator expectations, and its own history the reviewer remembers.
BPH
Where drugs and minimally invasive devices compete head-on, and the endpoint depends on which one you are.
Overactive Bladder
A diary-defined disease with a high placebo response and a well-worn but unforgiving trial design.
Pelvic Floor & Incontinence
Where the mesh reclassification rewrote the rules and every implant now carries long-term follow-up expectations.
Prostate Cancer
Reviewed by the Oncology Center of Excellence, with endpoints and accelerated-approval mechanics from a different world.
Endourology & Stones
Lasers, scopes, and lithotripsy in a mature 510(k) space where speed and predicate fit are the whole game.
Sexual & Reproductive Health
Where the endpoints are questionnaires, the safety signals are sensitive, and promotional review is unusually strict.
A bladder diary is a measuring device. Its recall window and compliance rules are reviewable — and they fail quietly.
In Half of Urology, the Endpoint Is Recorded at Home.
Overactive bladder, BPH symptoms, incontinence episodes — these are counted by patients in diaries, not measured by instruments in clinics. That makes the diary a regulated measuring device: its recall window, its electronic implementation, its training, and its compliance monitoring are all reviewable, and all fail quietly.
Add a placebo response that routinely reaches half the treatment effect and the design margin disappears. We treat diary methodology as core regulatory infrastructure — validated, agreed, and monitored — because in this field the measurement error is the trial's biggest risk.
The Center You File With Decides Everything Else.
In urology the first real decision is not the endpoint or the comparator — it is which regulator will read your submission.
CDER and CDRH review the same indications with incompatible expectations. The jurisdiction question comes first, and an RFD can settle it.
Much of the field's efficacy evidence is patient-recorded. Instrument validity and compliance monitoring are regulatory work, not operations.
After mesh, any device implanted in the lower urinary tract carries years of safety follow-up the sponsor must plan and fund from the start.
Six Failure Modes We Are Brought In to Prevent.
Most of these are jurisdiction and measurement problems wearing clinical clothing.
The wrong center
Building a device program against drug expectations, or a drug program against device timelines — and finding out at the pre-submission.
An unvalidated diary
Modifying the recall window or the electronic implementation of a validated diary and forfeiting the instrument's standing.
Placebo response ignored
Powering an OAB or BPH trial without accounting for a placebo effect that regularly reaches half the treatment benefit.
Mesh history underestimated
Bringing a pelvic-floor implant forward with follow-up plans written as though the reclassification never happened.
Sham control unplanned
Assuming a device trial can be open-label when the endpoint is symptomatic and the reviewer will insist on a sham.
Promotional overreach
Building claims in sexual and reproductive health that the label cannot carry and OPDP will act on.
Urology Regulatory Leadership Fluent in Both Centers.
Our urology leads have taken drugs through CDER on diary endpoints and devices through CDRH on flow rates and retreatment — and know when to ask for a jurisdiction determination.
"Urology punishes sponsors who assume. The same indication is two completely different programs depending on which center reads it — decide that deliberately, on day one."
The discipline we bring across BPH, overactive bladder, pelvic floor, prostate cancer, and endourology.
Planning a Urology Program? Settle the Jurisdiction Before the Protocol.
Bring senior urology regulatory leadership in while the center, the endpoint, and the comparator are still choices.
Senior-led. Embedded in your team. No junior hand-offs.